Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 9;295(2):631–644. doi: 10.1074/jbc.RA119.011137

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Aldahl et al.

Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

Figure 4. — Met enhances β-catenin–mediated tumor progression in xenograft model for prostate cancer. A, schematic representation of experimental design. B, graphical representation of weights of xenografts derived from H11^L-Met^/+:Ctnnb1^(Ex3)L^/+:PB-Cre4 or Ctnnb1^(Ex3)L^/+:PB-Cre4 mouse prostate tissues (left) or Ki67 expression (right) in prostate tissues of the indicated genotypes. Shown are representative images of H&E-stained prostate tumors from Ctnnb1^(Ex3)L^/+:PB-Cre4 (C) or H11^L-Met^/+:Ctnnb1^(Ex3)L^/+:PB-Cre4 (D) mice. C1–D2, high-magnification images from the indicated mice. Immunohistochemical analysis of Met (panels C4 and C5 and panels D4 and D5) and β-catenin (panels C6 and C7 and panels D6 and D7) in prostate tissues from the indicated mice. Scale bar, 50 μm (12.5 μm for high-magnification images).